天津医药

天津医药 ›› 2018, Vol. 46 ›› Issue (4): 391-393.doi: 10.11958/20171533

• 临床研究 • 上一篇    下一篇

血清白细胞介素-35水平与急性运动轴索型 神经病患者疾病严重程度的关系

朱思语，常生辉，丑丽莎，张大启，李立敏，杨丽△   

  1. 基金项目：国家自然科学基金资助项目（81471221）；天津市应用基础与前沿技术研究计划（重点项目）（15JCZDJC35700） 作者单位：天津医科大学总医院神经内科，天津市神经病学研究所（邮编300052） 作者简介：朱思语（1992），女，硕士在读，主要从事神经系统免疫性疾病的研究
  • 收稿日期:2017-12-29 修回日期:2018-02-24 出版日期:2018-04-15 发布日期:2018-04-15
  • 通讯作者: 杨丽 E-mail:yungli2001@yahoo.com
  • 基金资助:
    国家自然科学基金资助项目;天津市应用基础与前沿技术研究计划（重点项目）

The study on the relationship between serum level of interleukin-35 and disease severity of acute motor axonal neuropathy

ZHU Si-yu, CHANG Sheng-hui, CHOU Li-sha, ZHANG Da-qi, LI Li-min, YANG Li△   

  1. Department of Neurology, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Tianjin 300052, China
  • Received:2017-12-29 Revised:2018-02-24 Published:2018-04-15 Online:2018-04-15
  • Contact: YANG Li E-mail:yungli2001@yahoo.com

PDF (PC)

3679

摘要： 目的 探讨白细胞介素-35（IL-35）在急性运动轴索型神经病（AMAN）发病中的意义，以及其与疾病严重 程度和预后的相关性。方法 30例急性期患者（AMAN组）入院2周时采用GBS运动功能缺损评分（GDS）评估患者 的疾病严重程度，采用Erasmus吉兰-巴雷综合征预后评分（EGOS）评估患者6个月预后；另取30例健康志愿者作为 对照（HCs组）。用酶联免疫吸附测定法（ELISA）检测2组IL-35水平，并分析AMAN患者血清IL-35水平与疾病严重 程度及预后的相关性。依标准品对IL-35检测限度将AMAN患者分为低分泌组（＜0.13 μg/L）和分泌组（≥0.13 μg/L）， 比较2组GDS和EGOS水平差异。结果 AMAN组血清IL-35水平较HCs组明显降低，且AMAN患者急性期血清IL- 35水平与GDS和EGOS呈负相关（rs分别为-0.430和-0.523，均P＜0.05），低分泌组（17例）的GDS和EGOS均高于分 泌组（13例）。结论 IL-35可能参与了AMAN的发病过程，且作为一个保护性细胞因子，血清IL-35的水平有望作为 评估患者病情严重程度和预后的重要生物学标志物。

关键词: 吉兰-巴雷综合征, 酶联免疫吸附测定, 白细胞介素35, GBS运动功能缺损评分, Erasmus吉兰-巴雷综合 征预后评分, 急性运动轴索型神经病

Abstract: Objective To investigate the significance of interleukin-35 (IL-35) level in patients with acute motor axonal neuropathy (AMAN) and explore the correlation of the serum IL-35 level with disease severity and prognosis. Methods The GBS disability score (GDS) was used to assess the disease severity at 2 weeks after admission in 30 patients with AMAN (group AMAN). Erasmus GBS outcome score (EGOS) was used to evaluate the prognosis of patients in 6 months. Thirty healthy volunteers was used as control group (group HCs). Serum concentration levels of IL-35 were measured by enzyme-linked immunosorbent assay (ELISA). The correlation of the serum level of IL-35 with disease severity and prognosis in AMAN patients was analyzed. According to the standard of IL-35 detection, AMAN patients were subdivided into low secretory group (＜0.13 μg/L) and secretory group (≥0.13 μg/L), and GDS and EGOS levels were compared between the two groups. Results The serum level of IL-35 was significantly lower in group AMAN than that in group HCs. The serum level of IL-35 was negatively correlated with GDS and EGOS (rs=-0.430 and -0.523, P＜0.05). Values of GDS and EGOS were higher in low secretory group than those in the secretory group. Conclusion The serum level of IL-35 may participate in the pathogenic process of AMAN. As a protective cytokine, the serum level of IL-35 can be used as an important biomarker for the severity and outcomes of AMAN.

Key words: Guillain-Barre syndrome, enzyme-linked immunosorbent assay, interleukin-35, GBS disability score, erasmus GBS outcome score, acute motor axonal neuropathy